Interventions for acute non-arteritic central retinal artery occlusion

视网膜中央动脉阻塞 医学 视力 心理干预 随机对照试验 临床试验 荟萃分析 梅德林 验光服务 物理疗法 眼科 外科 内科学 精神科 政治学 法学
作者
John C. Lin,Sophia Song,Sueko M Ng,Ingrid U. Scott,Paul B. Greenberg
出处
期刊:The Cochrane library [Wiley]
卷期号:2023 (1) 被引量:3
标识
DOI:10.1002/14651858.cd001989.pub3
摘要

Acute non-arteritic central retinal artery occlusion (CRAO) occurs as a sudden interruption of the blood supply to the retina and typically results in severe loss of vision in the affected eye. Although many therapeutic interventions have been proposed, there is no generally agreed upon treatment regimen.To assess the effects of treatments for acute non-arteritic CRAO.We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (which contains the Cochrane Eyes and Vision Trials Register) (2022, Issue 2); Ovid MEDLINE; Embase.com; PubMed; Latin American and Caribbean Health Sciences Literature Database (LILACS); ClinicalTrials.gov; and the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP). We did not use any date or language restrictions in the electronic search for trials. We last searched the electronic databases on 15 February 2022.We included randomized controlled trials (RCTs) comparing any interventions with another treatment in participants with acute non-arteritic CRAO in one or both eyes. DATA COLLECTION AND ANALYSIS: We used standard Cochrane methodology and graded the certainty of the body of evidence for primary (mean change in best-corrected visual acuity [BCVA]) and secondary (quality of life and adverse events) outcomes using the GRADE classification.We included six RCTs with 223 total participants with acute non-arteritic CRAO; the studies ranged in size from 10 to 84 participants. The included studies varied geographically: one in Australia, one in Austria and Germany, two in China, one in Germany, and one in Italy. We were unable to conduct any meta-analyses due to study heterogeneity. None of the included studies compared the same pair of interventions: 1) tissue plasminogen activator (t-PA) versus intravenous saline; 2) t-PA versus isovolemic hemodilution, eyeball massage, intraocular pressure reduction, and anticoagulation; 3) nitroglycerin, methazolamide, mecobalamin tablets, vitamin B1 and B12 injections, puerarin and compound anisodine (also known as 654-2) along with oxygen inhalation, eyeball massage, tube expansion, and anticoagulation compared with and without intravenous recombinant tissue plasminogen activator (rt-PA); 4) transcorneal electrical stimulation (TES) with 0 mA versus with 66% of the participant's individual electrical phosphene threshold (EPT) at 20 Hz (66%) versus with 150% of the participant's individual EPT (150%) at 20 Hz; 5) ophthalmic artery branch retrograde thrombolysis versus superselective ophthalmic artery thrombolysis; and 6) pentoxifylline versus placebo. There was no evidence of an important difference in visual acuity between participants treated with t-PA versus intravenous saline (mean difference [MD] at 1 month -0.15 logMAR, 95% confidence interval [CI] -0.48 to 0.18; 1 study, 16 participants; low certainty evidence); t-PA versus isovolemic hemodilution, eyeball massage, intraocular pressure reduction, and anticoagulation (MD at 1 month -0.00 logMAR, 95% CI -0.24 to 0.23; 1 study, 82 participants; low certainty evidence); and TES with 0 mA versus TES with 66% of EPT at 20 Hz versus TES with 150% of EPT at 20 Hz. Participants treated with t-PA experienced higher rates of serious adverse effects. The other three comparisons did not report statistically significant differences. Other studies reported no data on secondary outcomes (quality of life or adverse events). AUTHORS' CONCLUSIONS: The current research suggests that proposed interventions for acute non-arteritic CRAO may not be better than observation or treatments of any kind such as eyeball massage, oxygen inhalation, tube expansion, and anticoagulation, but the evidence is uncertain. Large, well-designed RCTs are necessary to determine the most effective treatment for acute non-arteritic CRAO.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
神宝嘎li发布了新的文献求助10
刚刚
喜看财经发布了新的文献求助10
刚刚
2秒前
诗兰完成签到 ,获得积分10
3秒前
3秒前
活力的尔蓉完成签到,获得积分10
4秒前
科研通AI65的应助被热情毛巾采纳,获得10
6秒前
lei完成签到,获得积分10
6秒前
是why耶完成签到 ,获得积分10
6秒前
陆陆完成签到,获得积分10
6秒前
8秒前
星海种花完成签到 ,获得积分10
9秒前
山蒲完成签到 ,获得积分10
9秒前
猪大肠完成签到 ,获得积分10
11秒前
科研通AI6.2的应助被叶问采纳,获得10
14秒前
石头完成签到,获得积分10
15秒前
阔达晓蓝完成签到,获得积分20
15秒前
张小秉完成签到,获得积分10
15秒前
顾矜的应助被猪敏爱椰枣采纳,获得10
15秒前
妮妮完成签到 ,获得积分10
16秒前
苹果小蜜蜂完成签到,获得积分10
18秒前
syvshc的应助被石头采纳,获得10
19秒前
20秒前
chen完成签到,获得积分10
20秒前
郑浩完成签到,获得积分10
21秒前
22秒前
博士完成签到,获得积分10
24秒前
maclogos完成签到,获得积分10
29秒前
学霸业的应助被阔达晓蓝采纳,获得10
29秒前
中岛悠斗完成签到,获得积分10
33秒前
舒适青槐完成签到,获得积分10
36秒前
37秒前
哈哈哈完成签到 ,获得积分10
37秒前
yu完成签到 ,获得积分10
38秒前
39秒前
lili完成签到,获得积分10
41秒前
叶问发布了新的文献求助10
41秒前
姚怜南完成签到,获得积分10
42秒前
43秒前
动人的大树完成签到,获得积分20
43秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8190389
求助须知:如何正确求助?哪些是违规求助? 9577501
关于积分的说明 21852916
捐赠科研通 7789263
什么是DOI,文献DOI怎么找? 3436376
关于科研通互助平台的介绍 2560204
邀请新用户注册赠送积分活动 2483032